 | |
| Clinical data | |
|---|---|
| Other names | E2COA; Estradiol cyclooctylacetate; Estradiol 17β-cyclooctylacetate; Estra-1,3,5(10)-triene-3,17β-diol 17β-cyclooctylacetate |
| Routes of administration | By mouth |
| Drug class | Estrogen;Estrogen ester |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C28H40O3 |
| Molar mass | 424.625 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Estradiol cyclooctyl acetate (E2COA), orestradiol 17β-cyclooctylacetate, also known asestra-1,3,5(10)-triene-3,17β-diol 17β-cyclooctylacetate, is anestrogenmedication and anestrogen ester – specifically, the 17β-cyclooctylacetateester ofestradiol – which has been studied for use inhormone replacement therapy forovariectomized women and as ahormonal contraceptive in combination with aprogestin but was never marketed.[1][2][3][4] It has greateroralbioavailability than doesmicronized estradiol due toabsorption via thelymphatic system and hence partial bypassing offirst-pass metabolism.[4][1] It is approximately twice as potent as micronized estradiol orally and has a comparatively reduced impact onliver parameters such as changes insex hormone-binding globulin production.[4] It was investigated in combination withdesogestrel as abirth control pill, but resulted in unacceptablemenstrual bleeding patterns and was not further developed.[1]
 | Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |
